Table 2.
Prior treatment.
| Group 1 | Group 2 | ||
| Type of treatment | (n = 15) | (n = 74) | All (n = 89) |
| Number of patients (%) | |||
|
| |||
| Number of prior chemotherapy regimens | |||
| 0 | 1 (7) | 2 (3) | 3 (3) |
| 1 | 10 (67) | 25 (34) | 35 (39) |
| 2 | 4 (27) | 29 (39) | 33 (37) |
| ≥ 3 | 0 (0) | 18 (24) | 18 (20) |
| Median | 1 | 2 | 2 |
| Range | 0–2 | 0–6 | 0–6 |
|
| |||
| Prior chemotherapy | |||
| Anthracyclines | 13 (87) | 70 (95) | 83 (93) |
| Ifosfamide | 8 (53) | 59 (80) | 67 (75) |
|
| |||
| Anthracycline clinical resistance (a) | |||
| Resistant | 9 (60) | 37 (50) | 46 (52) |
| Sensitive | 4 (27) | 33 (45) | 37 (41) |
| Never exposed | 2 (13) | 4 (5) | 6 (7) |
|
| |||
| Prior radiotherapy | |||
| Yes | 5 (33) | 32 (43) | 37 (42) |
| No | 10 (67) | 42 (57) | 52 (58) |
(a)Anthracycline resistance: progression occurring while under anthracycline-containing treatment, within 3 months of completing palliative treatment or within 6 months of completing adjuvant treatment with anthracyclines.